0000000000402868

AUTHOR

Ming Qi

Calibration strategy of the JUNO experiment

We present the calibration strategy for the 20 kton liquid scintillator central detector of the Jiangmen Underground Neutrino Observatory (JUNO). By utilizing a comprehensive multiple-source and multiple-positional calibration program, in combination with a novel dual calorimetry technique exploiting two independent photosensors and readout systems, we demonstrate that the JUNO central detector can achieve a better than 1% energy linearity and a 3% effective energy resolution, required by the neutrino mass ordering determination. [Figure not available: see fulltext.]

research product

The Design and Sensitivity of JUNO's scintillator radiopurity pre-detector OSIRIS

The European physical journal / C 81(11), 973 (2021). doi:10.1140/epjc/s10052-021-09544-4

research product

Study of BESIII trigger efficiencies with the 2018 J/psi data

Using a dedicated data sample taken in 2018 on the $J/\psi$ peak, we perform a detailed study of the trigger efficiencies of the BESIII detector. The efficiencies are determined from three representative physics processes, namely Bhabha-scattering, dimuon production and generic hadronic events with charged particles. The combined efficiency of all active triggers approaches $100\%$ in most cases with uncertainties small enough as not to affect most physics analyses.

research product

Radioactivity control strategy for the JUNO detector

JUNO is a massive liquid scintillator detector with a primary scientific goal of determining the neutrino mass ordering by studying the oscillated anti-neutrino flux coming from two nuclear power plants at 53 km distance. The expected signal anti-neutrino interaction rate is only 60 counts per day, therefore a careful control of the background sources due to radioactivity is critical. In particular, natural radioactivity present in all materials and in the environment represents a serious issue that could impair the sensitivity of the experiment if appropriate countermeasures were not foreseen. In this paper we discuss the background reduction strategies undertaken by the JUNO collaboration…

research product

DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (CASTOR)

8036 Background: Daratumumab (D), a human, CD38-targeting mAb, is well tolerated and induces deep and durable responses in patients (pts) with RRMM. We provide an update of CASTOR (NCT02136134), a multicenter, phase 3, randomized study of DVd vs Vd in RRMM. Methods: All pts received ≥1 prior line of therapy (LOT) and were administered 8 cycles (Q3W) of Vd (1.3 mg/m2 SC bortezomib on days 1, 4, 8, and 11; 20 mg PO/IV dexamethasone on days 1-2, 4-5, 8-9, and 11-12) ± D (16 mg/kg IV once weekly in Cycles 1-3, every 3 weeks for Cycles 4-8, then every 4 weeks until progression). Bortezomib-refractory pts were ineligible. Minimal residual disease (MRD) was assessed upon suspected CR and at 6 and…

research product

Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR

research product

Observation of the doubly radiative decay η′→γγπ0

Based on a sample of 1.31 billion J/psi events collected with the BESIII detector, we report the study of the doubly radiative decay eta' -> gamma gamma pi(0) for the first time, where the eta' meson is produced via the J/psi -> gamma eta' decay. The branching fraction of eta' -> gamma gamma pi(0) inclusive decay is measured to be B(eta' -> gamma gamma pi(0))(Incl) = (3.20 +/- 0.07(stat) +/- 0.23(sys)) x 10(-3), while the branching fractions of the dominant process eta' -> gamma omega and the non-resonant component are determined to be B(eta' -> gamma omega) x B(omega -> gamma pi(0)) = (23.7 +/- 1.4(stat) +/- 1.8(sys)) x 10(-4) and B(eta' -> gamma gamma pi(0))(NR) = (6.16 +/- 0.64(stat) +/-…

research product

Precise Measurement of the e+e−→π+π−J/ψ Cross Section at Center-of-Mass Energies from 3.77 to 4.60 GeV

The cross section for the process e(+)e(-)-> pi(+) pi(-) J/psi is measured precisely at center-of-mass energies from 3.77 to 4.60 GeV using 9 fb(-1) of data collected with the BESIII detector operating at the BEPCII storage ring. Two resonant structures are observed in a fit to the cross section. The first resonance has a mass of (222.0 +/- 3.1 +/- 1.4) MeV/ c(2) and a width of (44.1 +/- 4.3 +/- 2.0)MeV, while the second one has a mass of (4320.0 +/- 10.4 +/- 7.0)MeV/c(2) and a width of (101.4(- 19.7)(+25.3) +/- 10.2) MeV, where the first errors are statistical and second ones are systematic. The first resonance agrees with the Y(4260) resonance reported by previous experiments. The precisi…

research product

JUNO sensitivity to low energy atmospheric neutrino spectra

Atmospheric neutrinos are one of the most relevant natural neutrino sources that can be exploited to infer properties about cosmic rays and neutrino oscillations. The Jiangmen Underground Neutrino Observatory (JUNO) experiment, a 20 kton liquid scintillator detector with excellent energy resolution is currently under construction in China. JUNO will be able to detect several atmospheric neutrinos per day given the large volume. A study on the JUNO detection and reconstruction capabilities of atmospheric $\nu_e$ and $\nu_\mu$ fluxes is presented in this paper. In this study, a sample of atmospheric neutrino Monte Carlo events has been generated, starting from theoretical models, and then pro…

research product

Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.

8040 Background: MM patients (pts) with high cytogenetic risk have poor outcomes. In CASTOR, D-Vd prolonged progression-free survival (PFS) vs bortezomib and dexamethasone (Vd) alone, and exhibited tolerability in RRMM pts. We conducted a subgroup analysis of D-Vd vs Vd in CASTOR, based on cytogenetic risk. Methods: Pts received ≥1 prior line of therapy. Cytogenetic risk was based on a combined analysis of next-generation sequencing (NGS) and fluorescence in situ hybridization/karyotype testing. High-risk pts had t(4;14), t(14;16), or del17p abnormalities. Standard (std)-risk pts were confirmed negative for all 3 abnormalities. Minimal residual disease (MRD; 10–5) was assessed via NGS usin…

research product

Neutrino Physics with JUNO

The Jiangmen Underground Neutrino Observatory (JUNO), a 20 kton multi-purpose underground liquid scintillator detector, was proposed with the determination of the neutrino mass hierarchy as a primary physics goal. It is also capable of observing neutrinos from terrestrial and extra-terrestrial sources, including supernova burst neutrinos, diffuse supernova neutrino background, geoneutrinos, atmospheric neutrinos, solar neutrinos, as well as exotic searches such as nucleon decays, dark matter, sterile neutrinos, etc. We present the physics motivations and the anticipated performance of the JUNO detector for various proposed measurements. By detecting reactor antineutrinos from two power plan…

research product

Precise Measurement of the e+e− → π+π−J/ψ Cross Section at Center-of-Mass Energies from 3.77 to 4.60 GeV

The cross section for the process e(+)e(-)-> pi(+) pi(-) J/psi is measured precisely at center-of-mass energies from 3.77 to 4.60 GeV using 9 fb(-1) of data collected with the BESIII detector operating at the BEPCII storage ring. Two resonant structures are observed in a fit to the cross section. The first resonance has a mass of (222.0 +/- 3.1 +/- 1.4) MeV/ c(2) and a width of (44.1 +/- 4.3 +/- 2.0)MeV, while the second one has a mass of (4320.0 +/- 10.4 +/- 7.0)MeV/c(2) and a width of (101.4(- 19.7)(+25.3) +/- 10.2) MeV, where the first errors are statistical and second ones are systematic. The first resonance agrees with the Y(4260) resonance reported by previous experiments. The precisi…

research product

Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial.

In the phase III CASTOR trial, daratumumab, bortezomib and dexamethasone (D-Vd) significantly extended progression-free survival compared with bortezomib and dexamethasone (Vd) alone in patients with relapsed/refractory multiple myeloma (RRMM). Here, we present patient-reported outcomes (PROs) from the CASTOR trial. PROs were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) and the EuroQol 5-dimensional descriptive system questionnaire. Treatment effects through Cycle 8 were measured by a repeated measures mixed-effects model. After Cycle 8, PROs were only collected for patients in the D-Vd group who con…

research product